Sign In
Buy INCY
$119.80
-0.800 (-0.663%)
At Close: Aug 05, 2026
3 Highly Rated Biotech Stocks for Your July Buy List
06:20am, Friday, 05'th Jul 2024
The healthcare sector continues to be a hotbed of innovation, with biotechnology leading the charge. From groundbreaking gene therapies to next-generation cancer treatments, biotech companies are push
This CrowdStrike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
01:32pm, Tuesday, 02'nd Jul 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
7 Undervalued Biotech Stocks to Buy for Big-Time Returns
02:18pm, Monday, 01'st Jul 2024
Every investment category must answer the big question, why? For undervalued biotech stocks, it comes down to advantaging a supremely relevant sector without paying full price.
Incyte: The Worst Has Been Avoided
08:12am, Sunday, 16'th Jun 2024
In recent months, Incyte's management has continued to delight investors by accelerating the pace of development of its anti-inflammatory treatments. On May 30, 2024, Incyte announced the completion o
Incyte Announces Final Results of Tender Offer
08:00am, Thursday, 13'th Jun 2024
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Final Results of Tender Offer.
Incyte Announces Preliminary Results of Tender Offer
08:00am, Tuesday, 11'th Jun 2024
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Preliminary Results of Tender Offer.
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 07'th Jun 2024
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Dublin, June 07, 2024 (GLOBE NEWSWIRE) -- The "Malignant Mesothelioma - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering.
Incyte Completes Acquisition of Escient Pharmaceuticals
04:05pm, Thursday, 30'th May 2024
WILMINGTON, Del. & SAN DIEGO--(BUSINESS WIRE)---- $INCY--Incyte Completes Acquisition of Escient Pharmaceuticals.
Incyte (INCY) Up 7.5% Since Last Earnings Report: Can It Continue?
12:37pm, Thursday, 30'th May 2024
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings
01:15pm, Tuesday, 21'st May 2024
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Expands Presence in Delaware through Acquisition of Two Downtown Wilmington Office Buildings.
Incyte to Present at Upcoming Investor Conference
08:00am, Tuesday, 21'st May 2024
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 8:00 a.m. (EDT) i
Here's Why Incyte (INCY) Stock is Up More Than 7% in a Week
01:26pm, Friday, 17'th May 2024
Incyte (INCY) rises 7% in a week as investors appreciated the company's buyback plan to boost returns.
How Does Incyte Stock's Decline During The 2022 Inflation Shock Compare With The 2008 Crash?
08:45am, Wednesday, 15'th May 2024
The stock price of Incyte Incyte , a biopharmaceutical company, trades at $58 per share, about 43% below its peak level of $100 seen in January 2021. INCY stock was trading at around $76 in early June
Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress
05:00pm, Tuesday, 14'th May 2024
WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASCO24--Incyte to Highlight Data From its Oncology Portfolio at the 2024 ASCO Annual Meeting and EHA2024 Congress.
